AIM ImmunoTech Inc. — Director's Dealing 2019

Mar 19, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2019-03-19

Reporting Person: EQUELS THOMAS K. (Director, Exec. Vice Chairman/CEO/Pres.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-19	Common Stock	P	13400	$0.1755	Acquired	811707	Direct